ClinicalTrials.gg
CompletedNCT00330915Updated Jul 21, 2009Results posted

A Study of Pemetrexed and Folic Acid Given Before Surgery (Neoadjuvant Treatment) to Patients With Rectal Cancer.

A Phase 2 interventional study of pemetrexed in Rectal Neoplasms, sponsored by Eli Lilly and Company. Completed at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-07-21.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
37
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies in Rectal Neoplasms with a site in Sweden — 15 open to participants now, 22 under way, 4 of them phase 3. Rectal Neoplasms · Sweden.

Enrollment
33rd of 40
37 · median 233
Started
2006
the only one that year
Phase 2
5 of 64
1 open now
Registered
7th of 64
by date

Among the 64 studies in Rectal Neoplasms with a site in Sweden, this one is the 33rd largest by enrollment of the 40 interventional ones that give a count, is the only one that started in 2006, is one of 5 in phase 2, and was the 7th registered.

Rectal Neoplasms

2,403 studies on the registry are indexed under Rectal Neoplasms; 589 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

15 of the 64 studies in Rectal Neoplasms with a site in Sweden are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 406 Rectal Neoplasms studies recruiting now, 211 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Rectal Neoplasms with a site in Sweden, or all of them as a file.
02

Study summary

The purpose of this study is to help answer the following research questions:

If the study drug Pemetrexed can help patients with rectal cancer; If molecular biological parameters are correlated respectively changing due to cytotoxic treatment with Pemetrexed; To evaluate adverse events

03

Conditions studied

  • Rectal Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • no prior therapy for rectal cancer
  • pathological/ cytological diagnosis of adenocarcinoma of the rectum. Patients must have operable rectal cancer that is amenable to surgery.
  • adequate organ function
  • (ECOG) Performance status 0 or 1
  • signed
  • at least 18 years of age
  • surgically sterile, (women) or compliant with a medically approved regimen during and for 6 months after the treatment.

Exclusion criteria

Exclusion Criteria:

  • concurrent administration of any other anti-tumor therapy
  • treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry
  • serious concomitant systemic disorders
  • previously completed or withdrawn from this study
  • pregnant or breast-feeding
  • second primary
  • history of significant neurological or mental disorder, including seizures or dementia
  • inability to interrupt aspirin or other nonsteroidal anto-inflammatory drugs (NSAIDs)
  • presence of third space fluid collections that cannot be controlled by drainage or other procedure prior to the study entry
  • inability or unwillingness to take folic acid, vitamin B12 or dexamethasone
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    A

    Drug: pemetrexed

Interventions

  • 500 mg/m2, intravenous (IV), every 21 days x 3 cycles

    Also known as: LY231514, Alimta

06

What researchers measure

Primary outcomes

  1. Feasibility of Pemetrexed Prior to Surgery

    Feasibility was defined as the ability to receive the total planned dose of Pemetrexed administered over a period of no more than 9 weeks permitting scheduling conflict. A ±5 percent variance in the calculated total dose was allowed.

    Time frame: 3 cycles (21-day cycles)

Secondary outcomes

  1. Pathological Complete Response (pCR)

    Pathological complete response was defined as the absence of any tumor cells.

    Time frame: surgery following 3 cycles (21-day cycles) of chemotherapy

  2. Number of Participants With Complete Tumor Resection

    Time frame: surgery following 3 cycles (21-day cycles) of chemotherapy

  3. Number of Participants Receiving Sphincter Saving Surgery

    Time frame: surgery following 3 cycles (21-day cycles) of chemotherapy

07

Results

Posted Jul 21, 2009

Participant flow

Participant flow — Overall Study
MilestonePemetrexed
Started37
Completed37
Not completed0

Outcome measures

PrimaryFeasibility of Pemetrexed Prior to Surgery

Feasibility was defined as the ability to receive the total planned dose of Pemetrexed administered over a period of no more than 9 weeks permitting scheduling conflict. A ±5 percent variance in the calculated total dose was allowed.

Time frame:
3 cycles (21-day cycles)
Reported as:
Number · participants
Feasibility of Pemetrexed Prior to Surgery
participantsPemetrexed
Feasibility - Yes33
Feasibility - No4
SecondaryPathological Complete Response (pCR)

Pathological complete response was defined as the absence of any tumor cells.

Time frame:
surgery following 3 cycles (21-day cycles) of chemotherapy
Reported as:
Number · participants
Pathological Complete Response (pCR)
participantsPemetrexed
Complete Response - Yes0
Complete Response - No1
Complete Response - Not Determined36
SecondaryNumber of Participants With Complete Tumor Resection
Time frame:
surgery following 3 cycles (21-day cycles) of chemotherapy
Reported as:
Number · participants
Number of Participants With Complete Tumor Resection
participantsPemetrexed
Number of Participants With Complete Tumor Resection37
SecondaryNumber of Participants Receiving Sphincter Saving Surgery
Time frame:
surgery following 3 cycles (21-day cycles) of chemotherapy
Reported as:
Number · participants
Number of Participants Receiving Sphincter Saving Surgery
participantsPemetrexed
Surgery - Yes25
Surgery - No12

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemetrexed———
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventPemetrexed
IleusGastrointestinal disorders5/37
Wound complicationInjury, poisoning and procedural complications3/37
DiarrhoeaGastrointestinal disorders2/37
Atrial fibrillationCardiac disorders1/37
Myocardial ischaemiaCardiac disorders1/37
Abdominal painGastrointestinal disorders1/37
VomitingGastrointestinal disorders1/37
PyrexiaGeneral disorders1/37
Anorectal infectionInfections and infestations1/37
InfectionInfections and infestations1/37
Most frequent other events
Showing 10 of 26
Most frequent other events
EventPemetrexed
FatigueGeneral disorders23/37
NauseaGastrointestinal disorders18/37
Lacrimation increasedEye disorders17/37
UrticariaSkin and subcutaneous tissue disorders9/37
DiarrhoeaGastrointestinal disorders7/37
Buttock painMusculoskeletal and connective tissue disorders7/37
HeadacheNervous system disorders7/37
Dry mouthGastrointestinal disorders6/37
PyrexiaGeneral disorders6/37
Mucosal inflammationGeneral disorders4/37

Baseline characteristics

Age Continuous
Age Continuous(years)Pemetrexed
Mean60.3 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)Pemetrexed
Female11
Male26
Region of Enrollment
Region of Enrollment(participants)Pemetrexed
Sweden37
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)Pemetrexed
0 - Fully Active37
1 - Ambulatory, Restricted Strenuous Activity0
2 - Ambulatory, No Work Activities0
3 - Partially Confined to Bed, Limited Self Care0
4 - Completely Disabled0
Histopathological Diagnosis
Histopathological Diagnosis(participants)Pemetrexed
G1 - Well-Differentiated3
G2 - Moderately Differentiated25
G3 - Poorly Differentiated3
Not Applicable4
Unspecified2
Race/Ethnicity
Race/Ethnicity(participants)Pemetrexed
Caucasian36
East Asian1
Blood Pressure
Blood Pressure(mm Hg)Pemetrexed
Systolic Blood Pressure136.5 ± 18.4
Diastolic Blood Pressure77.6 ± 9.1
Body Height
Body Height(centimeters)Pemetrexed
Mean173.4 ± 9.4

4 further baseline measures are reported on the registry.

08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Göteborg, 41685, Sweden
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2006, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2009, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2006
First posted
May 29, 2006
Start
Jun 2006
Primary completionActual
Jun 2008
CompletionActual
Jun 2008
Results first posted
Jul 21, 2009
Last update
Jul 21, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00330915
First posted
May 29, 2006
Start date
Jun 2006
Primary completion
Jun 2008
Completion
Jun 2008
Results posted
Jul 21, 2009
Last update
Jul 21, 2009

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5PM Eastern time (UTC/ GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemetrexed

Start the discussion